← The SEC Ephemeris: the whole map
Xspray Pharma AB nilotinib
In the graph: all 3 documents (9 pages).
- Application
- NDA 217644
- Ticker
- Xspray Pharma AB
- Product
- nilotinib
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- June 4, 2026 · October 7, 2025 · July 25, 2024
From FDA letters and SEC filings. Not investment or medical advice.